The safety of corticosteroid therapy in IGA nephropathy: analysis of a real-life Italian cohort

期刊论文
发表日期：

2024年10月6日

查看全文

Ivano Baragetti,
Lucia Del Vecchio,
Francesca Ferrario,
Federico Alberici,
Andrea Amendola,
Elisa Russo,
Serena Ponti,
Anna Maria Di Palma,
Antonello Pani,
Cristiana Rollino,
Domenico Giannese,
Giuliano Boscutti,
Annasara Sorrentino,
Carla Colturi,
Giuliano Brunori,
Roberta Lazzarin,
Fausta Catapano,
Mario Cozzolino,
Sandro Feriozzi,
Claudio Pozzi

摘要

Background

Systemic steroids are recommended for patients with IgA nephropathy (IgAN) and proteinuria. However, there are concerns about their safety due to an excess of serious adverse events (SAEs) in previous randomised trials. This study evaluates the incidence of SAEs in IgAN patients receiving different treatment regimens in clinical practice.

Methods

Multicentre, retrospective, observational cohort study of 1209 patients (M/F: 864/345, mean age: 41.73 ± 14.92 years) with biopsy-proven IgAN treated with renin angiotensin system (RAS) inhibitors (RASI) (n = 285), intravenous + oral steroids (n = 633), oral steroids (n = 99), steroids + immunosuppressants (n = 192).

Results

A total of 119 (9.8%) adverse events were reported, of which 67 (5.5%) were considered treatment-emergent, and 36 (2.9%) were SAEs (n = 23, 63.8% were infections). One patient died due to sepsis. A significant association was observed between AEs and immunosuppression [8 (2.8%) in RASI, 60 (9.4%) in steroids + immunosuppressants, 14 in oral steroids (14.1%) and 37 pts (19.2%) in steroids + immunosuppressants (p < 0.01)], age and estimated glomerular filtration rate (eGFR), but not with proteinuria and sex. On multivariate analysis, only older age was associated with the occurrence of SAEs.

Conclusions

According to our findings, the incidence of SAEs during therapy with steroids alone or associated with immunosuppressors is lower in everyday clinical practice than in randomised clinical trials.

Graphical Abstract